Loading...
NPI 1184379422 · Chicago, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Zoom Lab Inc is a clinical medical laboratory provider located in Chicago, Illinois. This profile covers 1 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Zoom Lab Inc |
| Address | 2721 W Peterson Ave Ste 108 |
| City | Chicago |
| State | IL |
| ZIP | 60659 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 15, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $13M |
| Medicaid | $64.8K |
ZOOM LAB INC’s billing footprint is overwhelmingly COVID-19 testing–focused: Medicare activity is entirely captured by K1034 (provision of nonprescription self-administered COVID-19 tests), while Medicaid volume is concentrated in SARS‑CoV‑2 nucleic acid testing and specimen collection codes U0003, G2023, and U0005. This mix indicates the entity operates primarily as a COVID test provider and processing hub rather than a broad clinical laboratory with diverse diagnostic lines.
Medicare revenue is completely concentrated in a single code family: the precomputed top‑3 Medicare codes account for 100.0% of Medicare revenue, with K1034 alone reporting 1.1M claims, $12 avg paid/claim, and $13M revenue. That single‑code concentration means Medicare receipts come essentially only from distribution of nonprescription self‑tests.
On Medicaid, revenue is also highly concentrated: the precomputed top‑3 Medicaid codes account for 95.3% of Medicaid revenue. The largest Medicaid contributor is U0003 (745 claims, $48 avg paid/claim, $35.8K revenue, 55.2% of Medicaid revenue), followed by G2023 (743 claims, $19 avg paid/claim, $14.1K, 21.8%) and U0005 (745 claims, $16 avg paid/claim, $11.9K, 18.4%), which together indicate the Medicaid business is concentrated in molecular PCR testing plus specimen collection.
The payer mix is heavily skewed toward Medicare in scale: lifetime Medicare revenue is $13M compared with $64.8K in Medicaid revenue, so the provider is effectively operating at Medicare scale while Medicaid represents a very small portion of overall receipts. This imbalance suggests operational and reimbursement sensitivity to Medicare policy and payment levels for its primary code set.
ZOOM LAB’s national competitive standing for its principal Medicare code is extreme: K1034 ranks #40 of 30143 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), marking the practice as an outlier leader in nonprescription self‑test provision on Medicare. By contrast, its in‑state Medicaid ranks are middling—U0003 ranks #153 of 350 (56th percentile), G2023 ranks #174 of 396 (56th percentile), and U0005 ranks #102 of 210 (52th percentile)—which characterizes the provider as a typical, unremarkable participant in state Medicaid SARS‑CoV‑2 testing markets.
Operationally, the raw volumes and per‑claim payments show different roles across payers: Medicare shows 1.1M claims for K1034 at $12 avg paid/claim generating $13M, while Medicaid reports 1.5K claims for K1034 at $2 avg paid/claim generating $3K alongside several hundred claims each for U0003, G2023, and U0005. These disparities imply the entity likely distributes large quantities of nonprescription tests billed to Medicare while performing smaller‑scale high‑throughput nucleic acid testing and specimen collection billed to Medicaid.
The provider has relatively recent enrollment history (NPI enumerated 2022-02-15 (~4 years ago)) and has achieved substantial Medicare revenue in a short window, suggesting rapid scale‑up of its COVID testing operations since enumeration. Such quick monetization through a narrow set of codes can reflect a business model built around pandemic‑era test distribution and processing.
From a business‑continuity perspective, revenue concentration creates exposure to demand or policy shifts: with the top 3 Medicare codes representing 100.0% of Medicare revenue and the top 3 Medicaid codes representing 95.3% of Medicaid revenue, changes to reimbursement, coding guidance, or public testing demand for the specific COVID codes (K1034, U0003, G2023, U0005) would materially affect overall revenue. Analysts should treat this profile as highly concentrated by both code and clinical service line when assessing financial and operational resilience.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,085,170 | $10 | $13M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 15 | 1,150 | 720 | $10 | $414.9K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 750 | $50 | $35.8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 740 | $20 | $14.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 750 | $20 | $11.9K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,520 | $1 | $3K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 153 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 102 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 174 | 400 | 550 | $20 | $90.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 18 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Zoom Lab Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.